LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

NewsGuard 100/100 Score

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care (LINCC™) Initiative. The LINCC™ Initiative is part of the Janssen Therapeutics commitment to improving access to care in underserved communities for those whose lives are impacted by HIV/AIDS.

The recipients for the 2012-2013 cycle each received charitable contributions of up to $30,000 in support of programs to address personal, societal and structural barriers to care for individuals diagnosed and living with HIV/AIDS. Since the LINCC™ Initiative began in 2010, Janssen Therapeutics has contributed nearly $1.6 million to 44 community-based HIV/AIDS organizations in rural and urban areas of unmet need.

During the past three years, LINCC™ funding has focused on the country's most at-risk populations for HIV infection according to the Centers for Disease Control and Prevention: women of color and African-American men who have sex with men. Activities supported through the LINCC™ Initiative cycle for 2012-2013 will also reach historically marginalized communities, such as incarcerated persons living with HIV/AIDS and the transgender community.

"The HIV epidemic is not going away and it often hits those in greatest need of care the hardest," said Carine Brouillon, President of Janssen Therapeutics. "We're proud that for the third year in row, the LINCC™ Initiative carries on our commitment to help improve access to care and health outcomes, while also addressing healthcare disparities among the HIV community."

This year's 16 recipients comprise a diverse range of organizations that serve HIV/AIDS communities across the United States including:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers receive NIH grant to help develop gene therapy for HIV